Buprenorphine/naloxone and methadone effectiveness for reducing craving in individuals with prescription opioid use disorder: Exploratory results from an open-label, pragmatic randomized controlled trial
PsiquiatriaSobre o estudo
- Desenho
- Ensaio clínico randomizado
- Nível de evidência
- 2 · Nova evidência
- Revista
- Drug and alcohol dependence
- Publicado em
- 17 ago 2022
- Citações
- 20
O resumo deste estudo é do publisher e não tem licença aberta: por isso mostramos aqui só os dados do estudo, e o texto fica na fonte original, nos links abaixo.
O estudo original
Buprenorphine/naloxone and methadone effectiveness for reducing craving in individuals with prescription opioid use disorder: Exploratory results from an open-label, pragmatic randomized controlled trial
Christina McAnulty, Gabriel Bastien, M Eugenia Socias, Julie Bruneau, Bernard Le Foll, Ron Lim, Suzanne Brissette, Omar Ledjiar, Stephanie Marsan, Annie Talbot et al.
Descritores MeSH
- Opioid-Related Disorders
- Buprenorphine
- Methadone
- Naloxone
- Narcotic Antagonists
- Prescriptions
- Opiate Substitution Treatment
- Buprenorphine, Naloxone Drug Combination
- Craving
- Humans
Veja também
Estudos relacionados
- Associations of Methadone and BUP/NX Dose Titration Patterns With Retention in Treatment and Opioid Use in Individuals With Prescription-Type Opioid Use Disorder: Secondary Analysis of the OPTIMA Study
- Sex-based effectiveness in buprenorphine/naloxone and methadone treatment for opioid use disorder: Findings from the OPTIMA trial
- Opioid agonist treatment outcomes among individuals with a history of nonfatal overdose: Findings from a pragmatic, pan-Canadian, randomized control trial
- Mediating effect of craving on the impact of buprenorphine/naloxone and methadone treatment on opioid use: Results from a randomized controlled trial